AtriCure Return on Equity (ROE) Growth & History (ATRC)
AtriCure's return on equity was −2.40% for fiscal 2025.
View full AtriCure company overviewAtriCure annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2.40% | +7.24 pp |
| 2024 | 2024-12-31 | −9.64% | −3.05 pp |
| 2023 | 2023-12-31 | −6.60% | +3.29 pp |
| 2022 | 2022-12-31 | −9.88% | −21.08 pp |
| 2021 | 2021-12-31 | 11.20% | +25.80 pp |
| 2020 | 2020-12-31 | −14.60% | −0.43 pp |
| 2019 | 2019-12-31 | −14.17% | −3.87 pp |
| 2018 | 2018-12-31 | −10.30% | +6.02 pp |
| 2017 | 2017-12-31 | −16.32% | +2.46 pp |
| 2016 | 2016-12-31 | −18.78% | −1.73 pp |
| 2015 | 2015-12-31 | −17.05% | −1.24 pp |
| 2014 | 2014-12-31 | −15.80% | +11.13 pp |
| 2013 | 2013-12-31 | −26.94% | +26.66 pp |
| 2012 | 2012-12-31 | −53.59% | −19.86 pp |
| 2011 | 2011-12-31 | −33.73% | −11.31 pp |
| 2010 | 2010-12-31 | −22.42% | — |
AtriCure quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.78% | +3.12 pp |
| Q1 2026 | 2026-03-31 | 0.02% | +1.50 pp |
| Q4 2025 | 2025-12-31 | 0.36% | +3.73 pp |
| Q3 2025 | 2025-09-30 | −0.06% | +1.64 pp |
| Q2 2025 | 2025-06-30 | −1.35% | +0.40 pp |
| Q1 2025 | 2025-03-31 | −1.47% | +1.40 pp |
| Q4 2024 | 2024-12-31 | −3.36% | −1.26 pp |
| Q3 2024 | 2024-09-30 | −1.69% | +0.26 pp |
| Q2 2024 | 2024-06-30 | −1.74% | −0.63 pp |
| Q1 2024 | 2024-03-31 | −2.88% | −1.46 pp |
| Q4 2023 | 2023-12-31 | −2.11% | −1.19 pp |
| Q3 2023 | 2023-09-30 | −1.96% | +0.75 pp |
| Q2 2023 | 2023-06-30 | −1.12% | +2.11 pp |
| Q1 2023 | 2023-03-31 | −1.42% | +1.79 pp |
| Q4 2022 | 2022-12-31 | −0.92% | +1.91 pp |
| Q3 2022 | 2022-09-30 | −2.71% | −24.94 pp |
| Q2 2022 | 2022-06-30 | −3.23% | +0.96 pp |
| Q1 2022 | 2022-03-31 | −3.21% | +1.00 pp |
| Q4 2021 | 2021-12-31 | −2.83% | +1.65 pp |
| Q3 2021 | 2021-09-30 | 22.23% | +23.42 pp |
| Q2 2021 | 2021-06-30 | −4.19% | −1.63 pp |
| Q1 2021 | 2021-03-31 | −4.21% | +2.70 pp |
| Q4 2020 | 2020-12-31 | −4.47% | +1.89 pp |
| Q3 2020 | 2020-09-30 | −1.19% | +2.56 pp |
| Q2 2020 | 2020-06-30 | −2.56% | −0.85 pp |
| Q1 2020 | 2020-03-31 | −6.91% | −4.61 pp |
| Q4 2019 | 2019-12-31 | −6.37% | −4.71 pp |
| Q3 2019 | 2019-09-30 | −3.75% | +0.73 pp |
| Q2 2019 | 2019-06-30 | −1.71% | −1.49 pp |
| Q1 2019 | 2019-03-31 | −2.31% | +4.14 pp |
| Q4 2018 | 2018-12-31 | −1.66% | −0.05 pp |
| Q3 2018 | 2018-09-30 | −4.47% | +0.05 pp |
| Q2 2018 | 2018-06-30 | −0.22% | +4.05 pp |
| Q1 2018 | 2018-03-31 | −6.45% | −0.26 pp |
| Q4 2017 | 2017-12-31 | −1.61% | +3.43 pp |
| Q3 2017 | 2017-09-30 | −4.52% | −0.65 pp |
| Q2 2017 | 2017-06-30 | −4.27% | +0.31 pp |
| Q1 2017 | 2017-03-31 | −6.18% | −0.90 pp |
| Q4 2016 | 2016-12-31 | −5.05% | +1.95 pp |
| Q3 2016 | 2016-09-30 | −3.87% | +0.96 pp |
| Q2 2016 | 2016-06-30 | −4.58% | −0.78 pp |
| Q1 2016 | 2016-03-31 | −5.29% | −1.26 pp |
| Q4 2015 | 2015-12-31 | −6.99% | −3.00 pp |
| Q3 2015 | 2015-09-30 | −4.83% | −4.49 pp |
| Q2 2015 | 2015-06-30 | −3.80% | −1.80 pp |
| Q1 2015 | 2015-03-31 | −4.03% | +3.42 pp |
| Q4 2014 | 2014-12-31 | −3.99% | +5.16 pp |
| Q3 2014 | 2014-09-30 | −0.35% | +7.04 pp |
| Q2 2014 | 2014-06-30 | −2.01% | +2.66 pp |
| Q1 2014 | 2014-03-31 | −7.45% | +0.15 pp |
| Q4 2013 | 2013-12-31 | −9.15% | +6.35 pp |
| Q3 2013 | 2013-09-30 | −7.39% | +10.63 pp |
| Q2 2013 | 2013-06-30 | −4.67% | +4.30 pp |
| Q1 2013 | 2013-03-31 | −7.60% | +3.10 pp |
| Q4 2012 | 2012-12-31 | −15.50% | −2.38 pp |
| Q3 2012 | 2012-09-30 | −18.02% | −11.01 pp |
| Q2 2012 | 2012-06-30 | −8.96% | −3.34 pp |
| Q1 2012 | 2012-03-31 | −10.70% | — |
| Q4 2011 | 2011-12-31 | −13.12% | — |
| Q3 2011 | 2011-09-30 | −7.00% | — |
| Q2 2011 | 2011-06-30 | −5.62% | — |
AtriCure return on equity trends
Over the last five fiscal years, AtriCure's return on equity increased from −14.60% to −2.40%, a change of +12.20 percentage points. The latest reported quarter, Q2 2026, shows 1.78%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AtriCure source filings ↗